PatientsVille.com Logo

Colitis and Pantecta

PatientsVille

Colitis Symptoms and Causes

Ulcerative Colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease.

UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include

  • Anemia
  • Severe tiredness
  • Weight loss
  • Loss of appetite
  • Bleeding from the rectum
  • Sores on the skin
  • Joint pain
  • Growth failure in children

About half of people with UC have mild symptoms.

Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for colitis

colitis treatment research studies

Pantecta clinical trials, surveys and public health registries


Find Drug Side Effect reports



Pantecta Side Effects

Death (22)
Gastrointestinal Haemorrhage (7)
Haemorrhage (5)
Hiatus Hernia (5)
Rib Fracture (5)
Chest Discomfort (4)
Nausea (4)
Osteoporosis (4)
Wheezing (4)
Dengue Fever (3)
Fall (3)
Bronchospasm (3)
Renal Failure (3)
Urticaria (3)
Syncope (2)
Colon Cancer (2)
Ulcer (2)
Neutropenia (2)
Anaemia (2)
Cardiac Failure (2)
Bone Densitometry (2)
Hepatic Failure (2)
Loss Of Consciousness (1)
Off Label Use (1)
Parotitis (1)
Neoplasm Malignant (1)
Myocardial Infarction (1)
Osteitis (1)
Myalgia (1)
Pallor (1)
Penile Ulceration (1)
Pruritus (1)
Pancreatic Carcinoma (1)
Metastasis (1)
Pain In Jaw (1)
Ovarian Cancer (1)
Agranulocytosis (1)
Bronchitis Bacterial (1)
Bronchopneumonia (1)
Anastomotic Leak (1)
Ocular Hyperaemia (1)
Dizziness (1)
Caesarean Section (1)
Cerebral Infarction (1)
Hernia Repair (1)
Hypoglycaemia (1)
Headache (1)
Hand Fracture (1)
Haemolytic Anaemia (1)
Metastases To Lung (1)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

A few days I stomachache and diarrhea. I think we enterocolitis. What medications can I take? Thank you in advance!Send your answer on my e-mail www.heprer22@yahoo.com

Coral, So sorry to hear about your UC. I'm 47 and have had it for 17 years but mostly in remission. Ask your Dr. about Librax, It really helps with the pain of UC when going to bathroom. Good luck and God Bless!

Enterocolitis viral

Hi , i am 14 and have been diagnosed with ulcerative colitis for a year now , after being treated i went into remission for about 7 months , but got a stomache flu and it flared up again , my dr wants me to go on prednisone i dont want to go on that

I am a 44 year old female with a mild case of ulcerative colitis that has been under control with no flare ups for many years thanks to the corticosteroid Lialds. It seems that for about the past year now I've been having frequent reoccurring vaginal

I am feeling swollen today is that cause i have uclerative colitis which i do have :'(

I want to know if you can loose weight by using pantecta

Noticed that my liver got swollen after being on Pantecta for five days.

Recently diagnosed with emphysemna, 50% lung capacity and together with other medecines was prescribed this drug Pantecta. Reading all these reports of patients that dies after some months after taking this medicament made me afraid. I am 69 years of

I have ulcerative colitis, I have had 9 treatments of Remicade and have decided to stop. I have a lympnode in my neck that is enlarged now, I am so so tierd all the time, I have nausea all the time and now get more allergic reactions to things. M

I'm taking Salazopyrin EN 500mg (2 tablets in the morning and 2 in the evening) for the treatment of ulcerative colitis. I have experienced unexplained high fever, aches and pains in my neck, pain behind my eyes and I'm feeling nauseou

At first I just felt tired for about 5 hours, then horrible flu like symptoms. Pain, migraine headache, fever, muscle aches, general feeling of pain and discomfort and fever, worsening of colitis symptoms. It was a horrible experience. I had to deba

Have been taking salofalk for a month, bleeding from the bowel, severe pains in the stomach, mild chest pain, constapated stool soft, I think i'm incontinent of bm, my bowels are not moving right, and i do have colitis

Hi , i am 14 and have been diagnosed with ulcerative colitis for a year now , after being treated i went into remission for about 7 months , but got a stomache flu and it flared up again , my dr wants me to go on prednisone i dont want to go on that

I also recieved Remicade for my Ulcerative Colitis and after that I developed Alopecia Areata (Alopecia Universalis) my Ulcerative colitis was treated.

I am a 44 year old female with a mild case of ulcerative colitis that has been under control with no flare ups for many years thanks to the corticosteroid Lialds. It seems that for about the past year now I've been having frequent reoccurring vaginal

I am experiencing hair loss. I have had 4 remicade infusions I don't take any other medication. I am taking it for ulcerative colitis.

I am feeling swollen today is that cause i have uclerative colitis which i do have :'(

I am taking Azathioprine for ulcerative colitis. I started this med more than a week ago. The one symptom I'm noticing the most is chest pain around the lower left ribs. I can't tell if the chest pain is a side effect of Azathioprine. My doctor said

Colitis Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe
Condition: Clostridium Difficile COLITIS
Intervention: Drug: Nu-Lytely
Outcome Measures: Length of stay;   Need for surgery
2 Not yet recruiting Golimumab Utilization and Impact on Ulcerative COLITIS (MK-8259-032)
Condition: Ulcerative COLITIS
Intervention: Drug: Golimumab
Outcome Measure: Proportion of Participants Meeting Partial Mayo Score Response Criteria at Week 54
3 Not yet recruiting Case-Control Study to Identify Risk Factors for Microscopic COLITIS
Conditions: Microscopic COLITIS;   Collagenous COLITIS;   Lymphocytic COLITIS
Intervention: Other: Blood sample
Outcome Measures: Assessment of environmental and hygiene-related risk factors for microscopic COLITIS;   The difference between the CC and LC subpopulation regarding environmental, hygiene-related, and generally known risk factors
4 Recruiting Fecal Microbiota Transplantation (FMT) for Treatment of Ulcerative COLITIS in Children
Condition: Ulcerative COLITIS
Intervention: Biological: Fecal Microbiota Transplant
Outcome Measures: Assess safety of FMT treatment by recording the frequency of adverse events.;   Assess efficacy of FMT treatment with the aid of the Pediatric Ulcerative COLITIS Activity (PUCAI) Index, a validated measure of clinical disease severity.
5 Not yet recruiting Stool Transplants to Treat Refractory Clostridium Difficile COLITIS
Condition: Clostridium Difficile COLITIS
Intervention: Biological: fecal microbiota
Outcome Measures: Recurrent COLITIS due to Clostridium difficile;   Tolerability of oral fecal microbiota transplantation;   Safety of oral fecal microbiota transplantation;   rate of repeat therapy for C. difficile COLITIS within 6 months of fecal microbiota transplantation.
6 Unknown  Safety and Activity of ORE1001 in Subjects With Ulcerative COLITIS
Condition: Mild to Moderate Ulcerative COLITIS
Interventions: Drug: ORE1001;   Drug: Placebo
Outcome Measures: The safety and tolerability of ORE1001 in subjects with ulcerative COLITIS as demonstrated by the frequency and severity of adverse events;   Change in the modified Baron Score from Baseline to Week 6;   Change in the Ulcerative COLITIS Clinical Score from Baseline;   Change in the partial Mayo Score fom baseline;   Calprotectin concentrations;   Riley Acute Inflammation Scale (histology);   Clinical remission
7 Recruiting A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative COLITIS
Condition: COLITIS, Ulcerative
Intervention: Drug: Golimumab
Outcome Measures: Serum golimumab concentrations at Week 6;   Area under the curve for serum golimumab concentration from Week 0 through Week 6;   Number of participants with adverse events as a measure of safety;   Number of participants who will achieve clinical response at Week 6;   Number of participants who will achieve clinical remission at Week 6 measured by the Mayo score;   Number of participants who will achieve clinical remission at Week 6 measured by Pediatric Ulcerative COLITIS Activity Index (PUCAI) score;   Number of participants with mucosal healing at Week 6;   Number of participants who will achieve clinical remission at Week 54 and Week 110 measured by Pediatric Ulcerative COLITIS Activity Index (PUCAI) score
8 Unknown  Usefulness of Chromoendoscopy in Diagnosing Microscopic COLITIS
Conditions: Chronic Diarrhoea;   Lymphocytic COLITIS;   Collagenous COLITIS
Intervention: Procedure: Colonoscopy with Indigo-Carmine Chromoendoscopy
Outcome Measure: Detection of microscopic COLITIS using chromoendoscopy
9 Not yet recruiting The Risk for Clostridium Difficile COLITIS During Hospitalization in Asymptomatic Carriers
Conditions: Clostridium Difficile;   COLITIS
Intervention:
Outcome Measures: Development of COLITIS;   Duration until development of COLITIS;   Severity of COLITIS
10 Unknown  Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative COLITIS
Condition: Ulcerative COLITIS
Intervention: Device: Granulocyte Monocyte Apheresis (GMA-Apheresis)
Outcome Measures: Proportion of patients in steroid free clinical remission defined by Mayo Score less or equal to 2 with no individual subscore >1 at week 24;   Steroid free remission (assessed by Mayo score);   Response at week 12 and 24 (defined by a decrease in Mayo Score > or = to 3 points;   Acute Phase reactants change at all lab analysis;   Rescue therapy requirements (new courses of steroids, cyclosporine, infliximab, or surgery) during study period;   Time to relapse;   · Clinical response according to the activity indexes Truelove & Witts, Powell Tuc, Rachmiliewitz (Clinical Activity Index), Lichtiger (Modified Truelove & Witts Severity Index), Walmsley (Simple Clinical COLITIS Index;   Clinical remission and response at weeks 12 and 24 analysed according to concomitant use of immunosupressants;   Adverse events
11 Recruiting Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative COLITIS Disease
Condition: Ulcerative COLITIS
Intervention: Device: Capsule Endoscopy
Outcome Measures: Agreement between PillCam IBD system and optical colonoscopy in the evaluation of UC disease extent (Non-active disease, Proctitis, Left-sided COLITIS, PanCOLITIS);   • Agreement between PillCam IBD system and optical colonoscopy in the evaluation of UC disease activity based on the Mayo Score (non-active, mild, moderate, severe)
12 Not yet recruiting Influence of ADA (Adalimumab) on Fecal Calprotectin, QoL (Quality of Life) and Workability of Patients Suffering From Ulcerative COLITIS
Condition: Moderate to Severe Ulcerative COLITIS
Intervention:
Outcome Measures: Change of Percentage of patients with fecal calprotectin level <= 150µg/g;   Change in patients quality of life measured with the short Inflammatory Bowel Disease Questionnaire (sIBDQ);   Change in patients workability measured with the Work Productivity and Activity Impairment (WPAI):UC questionnaire;   Correlation of fecal Calprotectin;   Correlation of fecal Calprotectin stratified by C-reactive protein (CRP) Levels;   Disease Activity Score (DAS);   Correlation of disease activity stratified to CRP Levels;   Correlation of quality of life stratified to CRP Levels;   Correlation of workability stratified to CRP Levels
13 Recruiting Transplantation of Faeces in Ulcerative COLITIS; Restoring Nature's Homeostasis
Condition: Ulcerative COLITIS
Interventions: Other: treatment with faecal transplantation (donor faeces);   Other: treatment with faecal transplantation (own faeces)
Outcome Measures: co-primary endpoint of clinical remission, as well as reduction of Mayo endoscopic inflammation score;   Simple clinical COLITIS activity index (SCCAI) score reduction;   Frequency of bowel movements;   Time to recurrence
14 Recruiting Thermography in Surveillance of Ulcerative COLITIS
Condition: Ulcerative COLITIS
Interventions: Device: Thermographic imaging;   Procedure: Colonoscopy
Outcome Measures: Number of Participants with Raised Abdomen Surface Temperature in centigrade;   Change from Baseline in Abdomen Surface Temperature at 1 year
15 Not yet recruiting Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative COLITIS
Condition: Ulcerative COLITIS
Interventions: Biological: Adalimumab;   Other: Placebo
Outcome Measures: Proportion of subjects who achieve clinical remission;   Proportion of subjects who responded at Week 8 per PMS and achieve clinical remission;   Proportion of subjects who achieve mucosal healing;   Proportion of subjects in Pediatric Ulcerative COLITIS Activity Index (PUCAI) remission
16 Unknown  Safety, Tolerability, Biomarker and Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative COLITIS
Conditions: Left-Sided Ulcerative COLITIS;   Proctosigmoiditis
Interventions: Drug: PUR 0110 Rectal Enema 250 mg;   Drug: PUR 0110 Rectal Enema 500 mg;   Drug: PUR 0110 Rectal Enema 1000 mg;   Drug: Placebo Enema
Outcome Measure: Incidence, nature and severity of adverse events and abnormal clinical laboratory test results
17 Recruiting Mucosal Immunity of Ulcerative COLITIS Patients Undergoing Therapy With Trichuris Suis Ova
Condition: Ulcerative COLITIS
Intervention: Drug: Trichuris suis ova
Outcome Measures: Change from baseline of mucus production at 12 weeks and 24 weeks as assessed by histopathology;   Change from baseline of effector lymphocyte populations (Th1, Th2, Th17, and T-regulatory cells) at 12 and 24 weeks as assessed by flow cytometry of peripheral blood mononuclear cells and isolated leukocytes from pinch biopsies;   Change from baseline of bacterial composition and attachment at 12 weeks and 24 weeks as assessed by real-time polymerase chain reaction and 454 sequencing of pinch biopsies and stool specimens;   Change from baseline of gene expression at 12 weeks and 24 weeks as assessed by microarray and real-time polymerase chain reaction analysis of pinch biopsies;   Change in Mayo score from baseline at 12 weeks and 24 weeks;   Change from baseline of the Simple Clinical COLITIS Activity Index at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 weeks
18 Unknown  Melatonin & Ulcerative COLITIS
Condition: Ulcerative COLITIS
Interventions: Dietary Supplement: Melatonin;   Other: Placebo
Outcome Measures: To estimate treatment effect of 12 weeks of 5 mg/day supplementation with melatonin on UC remission, and to use the estimate of this effect and its variability to calculate the sample size needed for a presumably larger and more definitive trial.;   Investigate whether responses to treatment vary according to certain other factors, such as age, sex, duration of disease, clinical symptoms, sleep duration and quality during the trial, and baseline endogenous melatonin.
19 Recruiting Evaluation of the Diagnostic Value of microRNAs for Inflammatory Bowel Diseases
Conditions: Ulcerative COLITIS,;   Crohn's Disease,;   Healthy;   Non-IBD COLITIS
Intervention: Device: qPCR diagnostic KIT of microRNAS
Outcome Measures: Evaluate the diagnostic value of microRNAs in qPCR,in IBD colon (ulcerative COLITIS or Crohn's disease) in adults compared to health;   - Evaluate the ability of miRNAs to discriminate a MC colic of UC in adults;   Evaluate the diagnostic value of microRNAs in inflammatory COLITIS child;   - Study the possibility of measuring miRNA of interest in feces and saliva
20 Unknown  Rituximab in Ulcerative COLITIS
Condition: Ulcerative COLITIS
Intervention: Drug: Rituximab
Outcome Measures: Remission defined as a decrease in Mayo score to ≤ 2 points at week 4;   Clinical response defined as a decrease in Mayo score by ≥ 3 points at weeks 4, 8 (partial Mayo score) and 12.;   Remission at weeks 8 and 12.;   Endoscopic mucosal healing at week 4 and 12;   Improvement in Inflammatory Bowel Disease specific Quality of Life Index [22] [Appendix 2] at weeks 4 and 12;   Histological improvement of disease activity at 4 and 12 weeks compared with baseline. Scored as follows:;   0 = no polymorphs;   1 = small numbers of polymorphs in the lamina propria with minimal infiltration of crypts;   2 = prominent polymorphs in the lamina propria with infiltration of ³ 50% of crypts;   3 = florid polymorph infiltrate with crypt abscesses;   4 = florid acute inflammation with ulceration;   Treatment tolerability as defined by adverse events.